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Pancreatic cancer is a rapidly fatal disease, with a 5-year survival
rate of less than 5% (Parker et al, 1997). Surgery has been con-
sidered the only curative modality for this disease even if at the
time of diagnosis the majority of patients have locally advanced
unresectable or metastatic disease (Kelly, 1995).
Until very recently, chemotherapy was held to be largely
ineffective in terms of objective responses, survival or quality of
life in advanced pancreatic cancer patients (Taylor, 1993; Lionetto
et al, 1995). However, opinions about the value of chemotherapy
in advanced pancreatic cancer are changing. Cautious optimism
for systemic chemotherapy is growing. This has been prompted by
new drugs and new treatment end points as quality of life and
symptom palliation. In fact, recent clinical trials with new drugs
that have included analysis of clinical benefit end points have
confirmed that chemotherapy is worthwhile and it can represent an
important tool for improving the patient conditions (Ahlgren,
1996; Schnall et al, 1996; Popescu et al, 1997).
Gemcitabine (GEM), a novel nucleoside analogue, is the most
investigated new drug in pancreatic cancer (Grindey et al, 1990).
In a randomized clinical trial, GEM was more effective than
5-fluorouracil (5-FU) (given at a dose of 600 mg m–2 intravenously
(i.v.) over 30 min, with the cycle defined as one 4-week period) in
alleviation of some disease-related symptoms and in survival
benefit for patients with advanced pancreatic cancer (Burris et al,
1997).
Because GEM and 5-FU work in different ways to inhibit DNA
and RNA synthesis and, furthermore, one of the effects of GEM,
the inhibition of ribonucleotide reductase, could lead to an
increased 5-FU activity (Heinemann et al, 1991), a study was
performed to determine if the combination of both drugs can
improve upon the results obtained with GEM alone.
PATIENTS AND METHODS
Patient selection
Patients with histologically verified, locally advanced unre-
sectable and/or metastatic pancreatic carcinoma were eligible
for the study. Other eligibility criteria included: measurable
disease, Karnofsky performance status (KPS) 60–90, age less
than 70 years, normal liver (serum bilirubin < 1.5 mg dl–1), renal
(serum creatinine < 1.5 mg dl–1) and bone marrow (leucocyte
count > 4000 ml–1, platelet count > 100 000 ml) functions.
Patients were excluded if they had undergone previous
chemotherapy. Patients who had had radiotherapy to individual
sites of disease were eligible but the disease site(s) was considered
non-evaluable for response.
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Summary In a randomized clinical trial, gemcitabine (GEM) was more effective than 5-fluorouracil (5-FU) in advanced pancreatic cancer
patients. GEM and 5-FU have different mechanisms of action and their combination, from a theoretical point of view, could result in a higher
activity. To test activity and feasibility of such a combination, a multi-institutional phase II study was initiated in November 1996 by the Italian
Group for the study of Digestive Tract Cancer (GISCAD). Primary objectives of this study were to determine the activity in terms of response
rate and clinical benefit, while the secondary objective was toxicity. According to the optimal two-stage phase II design, 54 patients were
enrolled. Schedule was: GEM 1000 mg m–2 intravenous (i.v.), and 5-FU 600 mg m–2 bolus i.v. weekly for 3 weeks out of every 4. All the 54
patients were symptomatic (pain, weight loss, dyspepsia). A clinical benefit was obtained in 28 patients (51%) (95% confidence interval (CI)
38–64%). Two patients achieved a partial response and 34 a stable disease. Median survival for all the patients was 7 months. Side-effects
were mild: no gastrointestinal or haematological grade 3–4 toxicity (WHO) were recorded. We observed only six episodes of grade 2 (WHO)
leukopenia and seven episodes of thrombocytopenia. Although the non-randomized design of this study suggests caution in the interpretation
of these data, in consideration of the low incidence of toxicity and the favourable results obtained in terms of clinical benefit, it may be
worthwhile to test more active schedules of 5-FU (continuous infusion) in combination with gemcitabine.
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Chemotherapy
GEM was diluted in normal saline and administered i.v. over
30 min at the dose of 1000 mg m–2. 5-FU was given as an i.v. bolus
at the dose of 600 mg m–2. Both drugs were administered once
weekly for 3 consecutive weeks out of every 4 weeks.
Treatment with GEM and 5-FU continued until there was
evidence of disease progression, or until there was significant
clinical deterioration because of tumour-related symptoms.
Patients were not allowed to receive concomitant radiation
therapy, chemotherapy, hormonal therapy or corticosteroids during
the trial.
Efficacy and safety evaluation
Clinical benefit
The principal efficacy end point used in this study was clinical
benefit derived from measurement of three common debilitating
signs or symptoms present in most patients with advanced
pancreas cancer: pain, functional impairment and weight loss
(Moore, 1996; Rothenberg et al, 1996a).
Pain assessment was comprised of separate measures of both
pain intensity and analgesic consumption. Each patient was cate-
gorized as positive, negative or stable for these two pain-related
outcomes. Pain intensity score as the 100 mm visual analogue
scale (0 = least possible pain to 100 = worst possible pain) was
recorded in a patient card completed daily. The weekly pain inten-
sity score was computed as the mean of the daily pain intensity
scores of the preceding 7 days. A positive change in pain intensity
was defined as at least 4 consecutive weeks during which the pain
intensity measurements were ³ 50% improved from baseline. A
negative change was defined as either ³ 4 consecutive weeks with
pain intensity measurements that were worse than baseline by any
degree, or discontinuation from study within the first 12 weeks of
treatment due to increasing pain. Pain intensity was considered
stable if the criteria for positive or negative change were not
met. Analgesic consumption was computed on a weekly basis as
the mean of the daily analgesic consumption (expressed in terms
of morphine equivalent mg per day) for the preceding 7 days. A
positive change in analgesic consumption was defined as ³ 4
consecutive weeks with analgesic consumption ≤ 50% compared
to baseline. Negative change in analgesic consumption was
defined as ³ 4 consecutive weeks with analgesic consumption that
was worse than baseline by any degree.
KPS was determined by two independent observers at baseline
and on a weekly basis thereafter. In cases where the scores
differed, the lower of the two scores was scheduled.
Clinical benefit response was determined by both pain assess-
ment classification and KPS. A patient was considered to be a
clinical benefit non-responder by the primary measures of
response if either pain or KPS was classified as negative. Barring
this occurrence, if either the pain or performance status measures
were positive a patient was identified as a clinical benefit
responder. If pain and performance status were both stable, then
the secondary measure of weight change was used to determine
clinical benefit. A patient’s weight was recorded once at baseline
and weekly thereafter. If the patient developed third-space fluid
or required parenteral nutrition at any time during the study, the
patient was considered non-positive for weight change. Positive
weight change was defined as an increase in weight by ³ 7% over
baseline that was sustained for at least 4 consecutive weeks. Any
other occurrence was defined as a non-positive change in weight.
Patients who were stable on pain assessment and performance
status were considered to be clinical benefit responders if they
experienced a positive change in weight.
Patients were categorized as clinical benefit non-responders if
they were stable on the primary measures and experienced a non-
positive change in weight.
For a patient to be classified as clinical benefit responder, at
least one component of clinical benefit response (e.g. pain, KPS or
weight change) must have been positive with none of the other
components negative.
Other measures of efficacy
In addition to the clinical benefit measurement, objective tumour
response and survival were assessed prospectively as additional
end points. Disease status for patients was assessed every 8 weeks.
Safety
Patients were evaluated by weekly history and physical examina-
tions, including complete blood counts and chemistry profile. All
signs, symptoms or laboratory abnormalities were assessed using
WHO criteria for toxicities (Miller et al, 1981).
Statistical methods
This was a multi-institutional phase II study; the primary objective
was to determine the activity of this combination (clinical benefit,
response rate) while secondary objective was to determine toxi-
city. According to the optimal two-stage phase II design the treat-
ment programme was designed to reject a clinical benefit less than
20% (p0) and to provide a statistical power of 90% in assessing the
activity of the regimen (in terms of response rate) as 40% (p1)
(p1–p0 = 20%) for an a error less than 0.05 (Simon, 1989).
The 95% exact confidence interval (CI) for response was
calculated. Survival time was calculated from the onset of
chemotherapy.
RESULTS
Investigators from nine GISCAD (Italian Group for the Study of
Digestive Tract Cancer) centres treated 54 advanced pancreatic
cancer patients with this weekly regimen between November 1996
and August 1997. The median follow-up from the start of treat-
ment was 10 months (range 6–14 months). The characteristics of
treated patients are detailed in Table 1. Thirty-eight patients
demonstrated a progressive disease in the 2 months before the
onset of chemotherapeutic treatment, either clinically or radio-
logically. None of the patients received radiation therapy for
primary tumour or metastatic disease.
Clinical benefit
Twenty-eight patients were classified as positive in the pain
category (i.e. pain intensity and/or analgesic use was reduced).
In ten patients both pain and KPS improved, while in the other
18 there was an improvement in pain with no worsening of
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clinical benefit responders by their primary measures.
With regard to the secondary measure of clinical benefit, seven
patients had a positive weight change. All of them had already
been categorized as clinical benefit responders by primary
measures. The other 21 patients achieving a clinical benefit,
i.e. had a stable weight.
The median time to achieve a clinical benefit response was
4 weeks, while the median duration of clinical benefit was 19
weeks.
Tumour response
All patients had bidimensionally measurable disease on computer-
ized tomography (CT) scan at study entry. Two patients achieved a
partial response, ten patients a minor response, while 24 had a
stable disease. The time to progression was 3.4 months. The
median survival was 7 months. Patients with partial response and
stable disease had a median survival of 9 months. The estimated
survival rate beyond 6 months was 61%, beyond 9 months was
35% and beyond 12 months was 22%.
Toxicity
Side-effects were mild: no gastrointestinal or haematological
grade 3–4 WHO toxicities were observed. We recorded only six
episodes of grade 2 leukopenia and seven episodes of grade 2
thrombocytopenia. We did not observe any treatment-related
death. Specific treatment-related toxicities are detailed in Table 2.
There was no cumulative toxicity in the following treatment
weeks.
DISCUSSION
In patients with pancreatic carcinoma, several chemotherapeutic
regimens have been tested with limited impact on patient outcome.
However, the development of new drugs and the introduction of
innovative end points of treatment have led to a cautious optimism
for the use of chemotherapy for advanced disease. In particular,
GEM, camptothecin derivatives such as topotecan or irinotecan, as
well as taxanes have been investigated for toxicity and activity in
advanced pancreatic cancer (Casper et al, 1994; Rougier et al,
1994; Carmichael et al, 1995; Wagener et al, 1995; Rothenberg
et al, 1996b; Scher et al, 1996; Whitehead et al, 1997).
GEM showed a very favourable toxicity profile and demon-
strated activity in advanced pancreatic cancer. It is a nucleoside
analogue, inhibiting DNA synthesis by the accumulation of difluo-
rodeoxycitidine triphosphate, which competes with deoxycitidine
triphosphate for incorporation into DNA (Grindey et al, 1990).
Furthermore, GEM seems to be a potent inhibitor of ribo-
nucleotide reductase. The inhibition of ribonucleotide reductase
limits the production of deoxyuridine monophosphate (Heinemann
et al, 1991). Because this effect can enhance 5-FU activity, by
decreasing the competition with fluorodeoxyuridine monophos-
phate, a combination of 5-FU with GEM can improve cell cyto-
toxicity.
We decided to combine GEM and 5-FU at the dose used in
the randomized trial by Burris et al (1997). The dose of 5-FU
(600 mg m–2) was not the maximum possible for treatment of
patients with pancreas cancer, but there is no evidence that either
a higher dose of 5-FU or modulation with leucovorin are more
effective (DeCaprio et al, 1991; Schnall et al, 1996). The schedule
of GEM was, in part, minimally modified with respect to that
proposed by Burris et al (1997), starting with the administrations
once a week for 3 consecutive weeks out of every 4 weeks. In fact,
in our previous experience on five patients treated with a weekly
administration for 7 consecutive weeks, the fourth administration
was always delayed (data not shown).
Tumour response rate was low (3.7%) and similar to that
obtained with GEM alone in the randomized trial. A minor
response was observed in ten patients. In spite of this low objective
response rate, 51% of patients treated in our study responded to
chemotherapy by achieving sustained improvement in pain, KPS,
or both. A clinical benefit was achieved in all the patients with a
partial or minor response, as well as in 16 patients with stable
disease, suggesting that in patients with advanced pancreatic
cancer a less than 50% decrease in measurable tumour bulk, or
even objectively measured stable disease, after treatment may be
associated with a clinical benefit. The discrepancy between
objective tumour response and clinical benefit could be due to the
difficulty to quantify the true proportion of tumour response in
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Table 1 Patient characteristics
No. of patients 54
Age (years)
Median 56
Range 47–70
Sex
M/F 36/18
Performance status (Karnofsky index)
80–90 14
60–70 40
Disease at presentation
Locally advanced 25
Metastatic 10
Locally advanced and metastatic 19
Site of primary tumour
Head 38
Body 12
Tail 4
Histology
Well-differentiated 15
Moderately differentiated 28
Poorly differentiated 11
Baseline pain intensity score
Median 45
Range 25–80
Median baseline analgesic requirement 90
(morphine equivalent mg day–1)
Previous treatments
Surgery 15
Radiotherapy 0
Table 2 Maximum toxicity observed for each patient
WHO grade
1 234
Leukopenia 4 6 – –
Thrombocytopenia 7 7 – –
Anaemia 6 2 – –
Diarrhoea 2 – – –
Nausea/vomiting 4 2 – –pancreatic tumour. In fact, since the important desmoplastic reac-
tion induced by the tumour, including inflammation and fibrosis
within and around the tumour, does not necessarly shrink after
chemotherapy, the size of tumour on a CT scan may not reflect the
true proportion of tumour response (Ahlgren, 1996). Therefore,
the use of clinical benefit as primary end point may be more useful
than tumour objective response in assessing the activity of
chemotherapy in pancreatic cancer.
This higher incidence of clinical benefit respect to that reported
in Burris’s study seems to indicate that the combination of GEM
and 5-FU could be more effective than GEM alone. Furthermore,
the survival rates at 6, 9 and 12 months were better in our study
than those reported in Burris’s study: 61%, 35% and 22% versus
46%, 24% and 18% respectively.
Therapy was well tolerated with no evidence of grade 3–4 toxi-
cities. It could be due to the modification of the schedule. In our
previous experience using the schedule proposed by Burris et al
(1997), most of the side-effects occur at week 5–6 of the first part
of treatment (7 consecutive weeks) and much less in the second
part of the therapeutic programme (once weekly for 3 out of every
4 weeks).
In conclusion, although the non-randomized design suggests
caution in the interpretation of results, considering the low inci-
dence of toxicity and the better results obtained in terms of clinical
benefit, it may be worthwhile to test more active schedules of 5-
FU (continuous infusion) in combination with GEM.
REFERENCES
Ahlgren JD (1996) Chemotherapy for pancreatic cancer. Cancer 78: 654–663
Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR,
Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA,
Stephens CD and Von Hoff DD (1997) Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with advanced
pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
Carmichael J, Fink U, Russel RCG, Spittle MF, Harris A and Spiessl G (1995) Phase
II study of gemcitabine in patients with advanced pancreatic cancer. Br J
Cancer 73: 101–105
Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD and Flombaum CD (1994)
Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas.
Invest New Drug 12: 29–35
DeCaprio JA, Mayer RJ, Gonin R and Arbuck SG (1991) Fluorouracil and high-dose
leucovorin in previously untreated patients with advanced adenocarcinoma of
the pancreas: results of a phase II trial. J Clin Oncol 9: 2128–2133
Grindey GB, Hertel LW and Plunkett W (1990) Cytotoxicity and antitumor activity
of 2¢,2¢-difluorodeoxycitidine (Gemcitabine). Cancer Invest 8: 313–318
Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W
(1991) Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2¢,2¢-
difluorodeoxycitidine. Mol Pharmacol 38: 567–572
Kelly DM and Benjamin IS (1995) Pancreatic carcinoma. Ann Oncol 6: 19–28
Lionetto R, Pugliese V, Bruzzi P and Rosso R (1995) No standard treatment is
available for advanced pancreatic cancer. Eur J Cancer 6: 882–887
Miller AB, Hoodgstraten B, Staquet M and Winkler A (1981) Reporting results of
cancer treatment. Cancer 47: 207–214
Moore M (1996) Activity of gemcitabine in patients with advanced pancreatic
carcinoma. A review. Cancer 78: 633–638
Parker SL, Tong T, Bold S and Wingo PA (1997) Cancer statistics, 1997. CA Cancer
Clin 47: 5–27
Popescu RA and Cunningham D (1997) Chemotherapy for advanced pancreatic
cancer. Some lights at the end of the tunnel? Ann Oncol 8: 415–416
Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM and
Wanebo HJ (1996) A rationale for expanding the endpoints for clinical trials in
advanced pancreatic carcinoma. Cancer 78: 627–632
Rothenberg LM, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA,
Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM and Von Hoff
DD (1996) A phase II trial of gemcitabine in patients with 5FU-refractory
pancreas cancer. Ann Oncol 7: 347–353
Rougier P, De Forni M, Adenis A, Ducreux M, Djazouli K, Adams D, Bonneterre J,
Clouet P, Blanc C, Bayssas M and Armand JP (1994) Phase II study of taxotere
in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13: 200
Schnall S and Macdonald JS (1996) Chemotherapy of adenocarcinoma of the
pancreas. Semin Oncol 23: 220–228
Scher MN, Kosierowski R, Lusch C, Alexander R, Fox S, Redei I, Green F, Raskay
B, Amfoh K, Engstrom PF and O’Dwyer PJ (1996) Phase II trial of topotecan
in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs
13: 347–354
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin
Trials 10: 1–10
Taylor I (1993) Should further studies of chemotherapy be carried out in pancreatic
cancer? Eur J Cancer 29: 1076–1078
Wagener DJT, Verdonk HER, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M,
Mathieu-Boué A and Verweij J (1995) Phase II trial of CPT11 in patients with
advanced pancreatic cancer, an EORTC early clinical trial group study. Ann
Oncol 6: 129–132
Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR and Macdonald JS
(1997) Phase II trial of paclitaxel and granulocyte colony-stimulating factor in
patients with pancreatic carcinoma: A Southwest Oncology Group Study.
J Clin Oncol 15: 2414–2419
1598 S Cascinu et al
British Journal of Cancer (1999) 80(10), 1595–1598 © 1999 Cancer Research Campaign